Nektar Therapeutics (NASDAQ:NKTR) Receives $2.33 Average Price Target from Analysts

Nektar Therapeutics (NASDAQ:NKTR) has earned an average recommendation of “Hold” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $2.33.

Separately, BTIG Research reaffirmed a “buy” rating and set a $4.00 price target on shares of Nektar Therapeutics in a research note on Monday, September 30th.

Hedge Funds Weigh In On Nektar Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. acquired a new stake in Nektar Therapeutics during the 2nd quarter valued at $29,000. Values First Advisors Inc. purchased a new position in shares of Nektar Therapeutics during the second quarter valued at $56,000. State Board of Administration of Florida Retirement System purchased a new stake in Nektar Therapeutics in the 1st quarter worth about $63,000. SG Americas Securities LLC boosted its position in Nektar Therapeutics by 63.0% during the 2nd quarter. SG Americas Securities LLC now owns 73,352 shares of the biopharmaceutical company’s stock worth $91,000 after acquiring an additional 28,338 shares during the period. Finally, Candriam S.C.A. acquired a new stake in Nektar Therapeutics during the 2nd quarter worth about $99,000. Institutional investors and hedge funds own 75.88% of the company’s stock.

Nektar Therapeutics Price Performance

NKTR opened at $1.23 on Thursday. Nektar Therapeutics has a 12 month low of $0.41 and a 12 month high of $1.93. The stock’s 50 day moving average price is $1.28 and its 200 day moving average price is $1.34. The stock has a market cap of $226.42 million, a P/E ratio of -1.37 and a beta of 0.61.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). The company had revenue of $23.49 million for the quarter, compared to the consensus estimate of $17.24 million. Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. During the same quarter in the prior year, the firm earned ($0.27) earnings per share. Equities analysts anticipate that Nektar Therapeutics will post -0.85 EPS for the current year.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.